Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Documents

49963

Sigma-Aldrich

β-tri-Calcium phosphate

puriss. p.a., ≥98% β-phase basis (sintered Powder)

Synonyme(s) :

β-TCP, β-Tricalcium phosphate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
Ca3O8P2
Numéro CAS:
7758-87-4
Poids moléculaire :
310.18
Numéro CE :
231-840-8
Numéro MDL:
MFCD00015984
Code UNSPSC :
12352302
ID de substance PubChem :
329757549
Nomenclature NACRES :
NA.55

Qualité

puriss. p.a.

Pureté

≥98% β-phase basis (sintered Powder)

Forme

powder

Impuretés

≤50 mg/kg total heavy metals as lead
≤500 mg/kg total sulfur as SO4 (ICP)

Traces d'anions

chloride (Cl-): ≤50 mg/kg

Traces de cations

As: ≤0.5 mg/kg
Ba: ≤20 mg/kg
Cd: ≤1 mg/kg
Co: ≤1 mg/kg
Cr: ≤10 mg/kg
Cu: ≤5 mg/kg
Hg: ≤0.5 mg/kg
Ni: ≤5 mg/kg
Pb: ≤5 mg/kg
Zn: ≤20 mg/kg

InChI

1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6

Clé InChI

QORWJWZARLRLPR-UHFFFAOYSA-H

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Application


  • Tungstosilicic Acid: A Promising Electrolyte for Redox Flow Battery.: This study explores the use of tungstosilicic acid (TSA) as an electrolyte in redox flow batteries (RFB). The research highlights TSA′s high energy density due to its multi-electron transfer capability, making it a promising candidate for enhancing the efficiency and power density of RFBs. This advancement is particularly relevant for large-scale energy storage systems integrating renewable energy technologies (Sharma et al., 2023).

  • Heterogenization of a Tungstosilicic Acid Catalyst for Esterification of Bio-Oil Model Compound.: This paper explores the heterogenization of tungstosilicic acid by supporting it on silica-based materials for the esterification of bio-oil model compounds. The catalyst shows high activity and stability, indicating its potential for industrial applications in bio-oil upgrading (Prasertpong et al., 2022).


Remarque sur l'analyse

Phase Composition (by XRD analysis):
ß-TCP: >98% ; Hydroxylapatite: <1.0% ; a-TCP: <0%; TTCP: 0%
other Ca-P phases as Calcium pyrophosphate <1.0%

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Simon Storgård Jensen et al.
Clinical oral implants research, 17(3), 237-243 (2006-05-05)
The purpose was to qualitatively and quantitatively compare the bone formation and graft resorption of two different bone substitutes used in both orthopedic and oral surgery, with autogenous bone as a positive control. Three standardized bone defects were prepared in
Crystal structure analysis of β-tricalcium phosphate Ca3(PO4)2 by neutron powder diffraction.
Yashima M, et al.
Journal of Solid State Chemistry, 175(2), 272-277 (2003)
S Yamada et al.
Biomaterials, 18(15), 1037-1041 (1997-08-01)
To study the influence of calcium phosphate ceramic solubility on osteoclastic resorption, neonatal rabbit bone cells were cultured for 2 days on hydroxyapatite (HA), beta-tricalcium phosphate (beta-TCP) and two types of biphasic calcium phosphate (BCP) with HA/beta-TCP ratios of 25/75
Michael D Weiden et al.
PloS one, 9(10), e108476-e108476 (2014-10-02)
While exploring the effects of aerosol IFN-γ treatment in HIV-1/tuberculosis co-infected patients, we observed A to G mutations in HIV-1 envelope sequences derived from bronchoalveolar lavage (BAL) of aerosol IFN-γ-treated patients and induction of adenosine deaminase acting on RNA 1
C Lorenzo et al.
Cancer gene therapy, 22(11), 542-551 (2015-10-10)
Interleukin 12 (IL12) is a heterodimeric proinflammatory cytokine that has shown promise as an anticancer agent. However, despite encouraging results in animal models, clinical trials involving IL12 have been unsuccessful due to toxic side effects associated with its systemic administration
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique